Form 4: Ionis Pharmaceuticals Director Allene M. Diaz Receives Equity Compensation

Ionis Pharmaceuticals Director Allene M. Diaz was granted non-qualified stock options and restricted stock units on July 1, 2025, as part of the company's established non-employee director compensation policy.

Summary

• Allene M. Diaz, a Director of Ionis Pharmaceuticals Inc. (IONS), was granted equity awards on July 1, 2025.
• The grants include 11,518 non-qualified stock options with an exercise price of $39.94 per share.
• Also granted were 5,220 Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Ionis common stock or its equivalent cash value.
• These grants were made under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan.
• The annual equity compensation for non-employee directors in 2025 is adjusted downward to total no more than $450,000, based on the aggregate grant date fair value as determined by FASB Topic ASC 718.
• Both the stock options and RSUs vest 100% on the earlier of the first anniversary of the grant date (July 1, 2026) or the next regularly scheduled annual meeting of stockholders.
• The stock options expire on June 30, 2035.
• RSU shares will be delivered to the reporting person on July 15th following the vesting date.

Sentiment

Score: 7

Explanation: The document reports a routine equity grant to a non-employee director, aligning their interests with shareholders, which is a standard corporate governance practice and generally viewed as a neutral to slightly positive event.

Positives

• Equity grants align the director's financial interests with those of shareholders, encouraging long-term value creation.
• The compensation is part of a defined Non-Employee Director Compensation Policy, indicating structured and transparent governance.

Future Outlook

The grants are structured to vest over time, aligning the director's future compensation with the company's performance up to the vesting date.

Industry Context

Granting equity awards to non-employee directors is a common practice across the biotechnology and pharmaceutical industries to attract and retain qualified board members and align their interests with long-term shareholder value.

Comparison to Industry Standards

• The document does not provide specific comparable companies, projects, or results to assess the grants against global benchmarks. However, equity compensation for directors is a standard practice in publicly traded companies, particularly in the biotech sector.

Stakeholder Impact

• Shareholders: The equity grants align the director's interests with long-term shareholder value, potentially leading to more focused decision-making for company growth.

Next Steps

• Vesting of 11,518 non-qualified stock options and 5,220 Restricted Stock Units on July 1, 2026, or the next annual meeting of stockholders, whichever is earlier.
• Potential exercise of vested stock options by Allene M. Diaz.
• Delivery of shares underlying the Restricted Stock Units on July 15th following their vesting date.

Key Dates

Recommendation

Keywords

Ionis Pharmaceuticals, IONS, SEC Form 4, Insider Transaction, Equity Grant, Stock Options, Restricted Stock Units, Director Compensation, Allene M. Diaz, Corporate Governance